CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading compound profile…

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Cannabinoids/Palmitoyl ethanolamide

Endocannabinoids

Palmitoyl ethanolamide

An <em>N</em>-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.

Definition: CHEBI:71464 · Chemical Entities of Biological Interest · release 253

Anandamide (16:0)hexadecanoyl ethanolamideHydroxyethylpalmitamideMonoethanolamine palmitic acid amideN-(2-hydroxyethyl)hexadecanamideN-(2-Hydroxyethyl)palmitamideN-hexadecanoylethanolamineN-palmitoylethanolaminepalmidrolpalmidrolumPalmitamide MEAPalmitic acid monoethanolamidePalmitinsaeure-beta-hydroxyethylamidPalmitoyl-EApalmitoyl ethanolamidePalmitoylethanolamidePEA

188public articles

11registered condition areas

All documents →

Identity & provenance

Chemical identity

C18H37NO2 · molecular weight 299.499

CAS: cas:544-31-0↗CHEBI: CHEBI:71464↗DRUGCENTRAL: drugcentral:2045↗HMDB: hmdb:HMDB0002100↗INCHI: InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)↗INCHIKEY: HXYVTAGFYLMHSO-UHFFFAOYSA-N↗KEGG.COMPOUND: kegg.compound:C16512↗KEGG.DRUG: kegg.drug:D08328↗LINCS.SMALLMOLECULE: lincs.smallmolecule:LSM-3518↗LIPIDMAPS: lipidmaps:LMFA08040013↗PATENT: patent:CA2738117↗PATENT: patent:EP2276461↗PATENT: patent:US2011046225↗PATENT: patent:US2011171313↗PATENT: patent:WO2009133574↗PATENT: patent:WO2011027373↗PUBCHEM_CID: 4671↗PUBMED: pubmed:16715117↗PUBMED: pubmed:18501510↗PUBMED: pubmed:19395322↗

Sources: ChEBI · 253 PubChem computed properties · pug-56197c22bd374f6b

0 referenced plant-occurrence records. They are identity candidates, not clinical evidence.

Research areas

Conditions found alongside this compound

Document links and organism occurrence are candidates, not proof of efficacy, safety or a treatment recommendation.

Epilepsy and cannabinoids

6 matching public articles

Candidate association · not a treatment claim

Chronic pain and cannabinoids

15 matching public articles

Candidate association · not a treatment claim

Multiple sclerosis and cannabinoids

4 matching public articles

Candidate association · not a treatment claim

Parkinson disease and cannabinoids

3 matching public articles

Candidate association · not a treatment claim

Alzheimer disease and cannabinoids

7 matching public articles

Candidate association · not a treatment claim

Anxiety disorders and cannabinoids

3 matching public articles

Candidate association · not a treatment claim

Post-traumatic stress disorder and cannabinoids

3 matching public articles

Candidate association · not a treatment claim

Migraine disorders and cannabinoids

2 matching public articles

Candidate association · not a treatment claim

Inflammatory bowel diseases and cannabinoids

5 matching public articles

Candidate association · not a treatment claim

Opioid-related disorders and cannabinoids

1 matching public articles

Candidate association · not a treatment claim

Depressive disorders and cannabinoids

3 matching public articles

Linked local records

Medicines and registered studies

Links use source-reported active ingredients or study intervention names and remain candidates, not treatment claims.

Medicines with this active ingredient

No public medicine record matched.

Registered studies

18 exact source-intervention matches.

Results postedCOMPLETED

A Randomized Controlled Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression

Palmitoylethanolamide (PEA)

Protocol onlyNOT_YET_RECRUITING

The Effect of Palmitoylethanolamide on the Clinical Outcomes in Ulcerative Colitis Patients

Palmitoylethanolamide (PEA)

Protocol onlyCOMPLETED

Effects on Sleep Quality and Bioelectrical Parameters of Cellular Health After Administration of a Plant Protein Supplement Combined With Ashwagandha and Rhodiola

Plant Protein Supplement

Protocol onlyRECRUITING

Recovery Following a Prolonged Period of Intensified Exercise Training: Evaluating the Impact of Levagen+® on Alleviating Physical, Physiological and Psychological Stress.

Levagen+® Palmitoylethanolamide (PEA)

Protocol onlyCOMPLETED

Investigating the Effects of Palmitoylethanolamide (PEA) on Stress, Craving and Pain in Opioid Use Disorder

Palmitoylethanolamide

Results postedACTIVE_NOT_RECRUITING

Treatment of Established Chemotherapy-Induced Neuropathy With N-Palmitoylethanolamide, a Cannabimimetic Nutraceutical: A Randomized Double-Blind Phase II Pilot Trial

Palmidrol

Protocol onlyCOMPLETED

Mechanisms of Palmitoylethanolamide (PEA) to Alter Pain Sensitivity in Knee Osteoarthritis

Latest documents

Recent research

2026

A Minimally Invasive LC-MS/MS Approach for Assessing Endocannabinoids in Saliva and Capillary Blood Microsamples.

Biosensors · Free full text

2026

Palmitoylethanolamide (PEA) regulates cell cycle progression and promotes an anti-inflammatory transcriptomic signature in C2C12 skeletal muscle cells.

Physiological Reports · Free full text

2026

Probiotics and palmitoylethanolamide (PEA) for osteoarthritic pain: individual effects in a multiple baseline design study.

BMC Complementary Medicine and Therapies · Free full text

2026

Low-dose combination of ultramicronized palmitoylethanolamide and docosahexaenoic acid on neurosteroid and neuroinflammatory dysregulation in autism spectrum disorders.

Neurotherapeutics · Free full text

2026

Regulation of Cholesterol and Triglyceride Metabolism by Fatty acid Ethanolamides.

Current Atherosclerosis Reports · Free full text

2026

Sex-specific differences in nociceptive behaviour and the amygdala endocannabinoid system in the rat monoiodoacetate-induced knee osteoarthritis model

Neurobiology of Pain · Free full text

2026

Changes in Vascular, Lymphatic, Inflammatory, and Lipid Mediators During a 7-Month Calorie-Restricted Low-Carbohydrate, High-Fat Dietary Intervention in Women with Lipedema: A Preliminary Prospective Study.

Ontology definitions normalize terms; they do not establish medical claims.

Candidate association · not a treatment claim

palmitoylethanolamide

Protocol onlyUNKNOWN

Unraveling the Spectrum of Migraine Resistant to Treatments: Searching for Novel Biological PHEnotypes and theRApeutic Approaches (SPHERA Project)

Palmitoyl ethanolamide

Protocol onlyCOMPLETED

Enhancing the Benefits of Blueberry Polyphenols With Plant and Whey Proteins

Blueberries and Pea Protein

Protocol onlyCOMPLETED

Athlete Whey Protein Sensitivity: Prevalence and Performance

Pea Protein Isolate, Rice Protein Concentrate, Hemp Protein

Protocol onlyRECRUITING

The Supplementation Therapy in Autism and Response to Treatment (START) Study

Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form

Protocol onlyUNKNOWN

Endocannabinoid Activity Remodulation for Psychosis Liability in Youth (EARLY)

Ultra-micronized Palmitoylethanolamide (PEA)

Browse all matching studies →

Nutrients · Free full text

2026

Enhancing anandamide signalling through fatty acid amide hydrolase inhibition: An update on the pharmacological strategy for treating psychiatric disorders.

Translational Psychiatry · Free full text

2026

Sex-specific association between low oral doses of cannabidiol (CBD) and plasma concentration of anandamide (AEA), N-palmitoylethanolamine (PEA) and N-oleoylethanolamine (OEA) in healthy occasional cannabis users.

Journal of Cannabis Research · Free full text

2026

Endocannabinoid dynamics across marathon and ultramarathon running: evidence from two field studies

BMC Medicine · Free full text

2026

Astrocytic GPR55 receptors promote glycolysis.

Journal of Cannabis Research · Free full text

2025

Cannabis and cannabinoids in dermatology: a systematic review and meta-analysis of quantitative outcomes.

Frontiers in Pharmacology · Free full text